Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 13/20 | 0.44 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92986 | 0.85 | LMNA (0.59) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL2466435 | 0.79 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL17228662 | 0.79 | KCNA2 (0.43) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL9263666 | 0.79 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL9264609 | 0.79 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL21261241 | 0.79 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL31447811 | 0.79 | LMNA (0.60) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL7100551 | 0.78 | LMNA (0.54) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL10808024 | 0.78 | LMNA (0.55) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL81547 | 0.78 | LMNA (1.00) | LMNAGAAKMT2AALDH1A1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57079858-A | — | — | None | — | — | JP | disclosed |
| WO-2019153954-A1 | MULTI-SUBSTITUTED BENZENE COMPOUND HAVING BIOLOGICAL ACTIVITY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 广州自远生物科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-9458142-B2 | Substituted quinones or analogues as colouring agents | MERCK PATENT GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150315177-A1 | SUBSTITUTED QUINONES OR ANALOGUES AS COLOURING AGENTS | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-8252356-B2 | Flavor composition or fragrance composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20110171358-A1 | Flavor composition or fragrance composition | OGURA MIHARU | 2011-07-14 | — | — | US | disclosed |
| EP-1944354-B1 | FLAVOR COMPOSITION OR FRAGRANCE COMPOSITION, AND FLAVOR-IMPROVING AGENT | TAKASAGO PERFUMERY CO LTD (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-2010535-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080213451-A1 | Flavor Composition or Fragrance Composition, and Flavor-Improving Agents | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1944354-A1 | FLAVOR COMPOSITION OR FRAGRANCE COMPOSITION, AND FLAVOR-IMPROVING AGENT | Takasago International Corporation (JP) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007120098-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| JP-S5779858-A | REMOVING OR REDUCING METHOD OF OFFENSIVE SMELL OF SOUP STOCK, DECOCTION OF CRUDE DRUG AND EXTRACT BY ADDITION OF MALTOL | OKAMURA KAZUHIRO | 1982-05-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315177-A1 | SUBSTITUTED QUINONES OR ANALOGUES AS COLOURING AGENTS | KRT18, IK, SDHA | LMNA 1112/4885GAA 4363/4885KMT2A 944/4885 |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | LMNA 1000/4885GAA 517/4885KMT2A 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.